Holen Sie sich die Stockscreener-App
3.63
11.25%
-0.46
Handel nachbörslich:
3.63
Schlusskurs vom Vortag:
$4.09
Offen:
$4.04
24-Stunden-Volumen:
1.10M
Relative Volume:
6.85
Marktkapitalisierung:
$118.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-87.23M
KGV:
-1.239
EPS:
-2.9299
Netto-Cashflow:
$-82.77M
1W Leistung:
-22.44%
1M Leistung:
-17.50%
6M Leistung:
-78.39%
1J Leistung:
-44.15%
1-Tages-Spanne:
$3.60
$4.19
1-Wochen-Bereich:
$2.90
$4.71
52-Wochen-Spanne:
$2.90
$19.30
Pepgen Inc Stock (PEPG) Company Profile
Firmenname
Pepgen Inc
Sektor
Branche
Telefon
703-456-8000
Adresse
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Vergleichen Sie PEPG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
3.63 | 118.32M | 0 | -87.23M | -82.77M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-07-31 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-21 | Eingeleitet | H.C. Wainwright | Buy |
Pepgen Inc Aktie (PEPG) Neueste Nachrichten
Wedbush Comments on PepGen’s FY2028 Earnings (NASDAQ:PEPG) - Defense World
Fmr LLC Sells 327,160 Shares of PepGen Inc. (NASDAQ:PEPG) - Defense World
Wedbush Has Bullish Forecast for PepGen FY2028 Earnings - MarketBeat
FDA Pauses PepGen’s DMD Drug Trial in the US - AJMC.com Managed Markets Network
PepGen stock craters 35% on FDA clinical hold - MSN
PepGen (NASDAQ:PEPG) Downgraded by Bank of America to Underperform - Defense World
FDA halts PepGen's DMD trial; ongoing study continues By Investing.com - Investing.com Australia
PepGen stock touches 52-week low at $2.9 amid market challenges - Investing.com
FDA halts PepGen's DMD trial; ongoing study continues - Investing.com India
PepGen shares downgraded to Underperform by BofA amid uncertainty over clinical hold - Investing.com
PepGen stock down 22% on FDA clinical hold (update) (PEPG:NASDAQ) - Seeking Alpha
PepGen stock touches 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa
Novo builds up manufacturing; Pepgen Duchenne trial put on hold - BioPharma Dive
Déjà Vu for PepGen as FDA Places Hold on DMD Drug - BioSpace
PepGen Shares Tumble Premarket as FDA Puts Study on Clinical Hold - MarketWatch
PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy - Business Wire
When (PEPG) Moves Investors should Listen - Stock Traders Daily
Frazier Life Sciences Management L.P. Sells 800,094 Shares of PepGen Inc. (NASDAQ:PEPG) - MarketBeat
PepGen Inc. (NASDAQ:PEPG) Shares Bought by Janus Henderson Group PLC - MarketBeat
PepGen Inc. (NASDAQ:PEPG) Shares Acquired by Suvretta Capital Management LLC - MarketBeat
Myotonic Dystrophy Clinical Trial Pipeline Boom as Over 20 Companies Leading the Charge in Research and Development | DelveInsight - Yahoo Finance
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development - Business Wire
Two new option listings and one option delisting on November 21st - TipRanks
PepGen Grants 95,000 Share Options to New Clinical Development SVP | PEPG Stock News - StockTitan
Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation - Simply Wall St
BofA lowers PepGen stock target as trial delays and competition weigh on outlook - Investing.com
Bank of America Cuts PepGen (NASDAQ:PEPG) Price Target to $6.00 - MarketBeat
PepGen price target lowered to $6 from $10 at BofA - TipRanks
Janus Henderson Group PLC's Strategic Acquisition of PepGen Inc Shares - GuruFocus.com
Leerink Partnrs Issues Positive Forecast for PepGen Earnings - MarketBeat
PepGen (NASDAQ:PEPG) Price Target Cut to $12.00 by Analysts at Wedbush - MarketBeat
PepGen (NASDAQ:PEPG) Earns "Buy" Rating from HC Wainwright - MarketBeat
PepGen Inc (PEPG) Quarterly 10-Q Report - Quartz
PepGen reports Q3 EPS (66c), consensus (87c) - TipRanks
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - BioSpace
PepGen Reports Improved Q3 Loss, $138.9M Cash Runway Extends to 2026 - StockTitan
We're Keeping An Eye On PepGen's (NASDAQ:PEPG) Cash Burn Rate - Yahoo Finance
Objective long/short (PEPG) Report - Stock Traders Daily
PepGen to Participate in Upcoming Investor Conferences - Business Wire
(PEPG) Technical Data - Stock Traders Daily
(PEPG) Proactive Strategies - Stock Traders Daily
PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society - Business Wire
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher - Benzinga
When the Price of (PEPG) Talks, People Listen - Stock Traders Daily
PepGen Inc. Announces Christopher Ashton to Retire from Its Board of Directors, Effective September 30, 2024 - Marketscreener.com
PepGen director Christopher Ashton to retire at month's end - Investing.com
PepGen director Christopher Ashton to retire at month's end By Investing.com - Investing.com Australia
PepGen Inc. Board Reshuffles as Ashton Plans Retirement - TipRanks
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors - Business Wire
Sofinnova Investments Inc. Has $8.96 Million Holdings in PepGen Inc. (NASDAQ:PEPG) - MarketBeat
Investigation announced for Investors who lost money with - openPR
Finanzdaten der Pepgen Inc-Aktie (PEPG)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):